Tenaya Therapeutics (TNYA)

Executive Summary

Tenaya Therapeutics is a clinical-stage biotechnology company developing genetic medicines for inherited heart diseases, primarily cardiomyopathies. Its lead program, TN-201, is an AAV-based gene therapy targeting MYBPC3 mutations for hypertrophic cardiomyopathy (HCM), currently in Phase 1 clinical trials with initial data expected in 2026. The pipeline also includes TN-401 (PKP2 gene therapy for arrhythmogenic right ventricular cardiomyopathy, ARVC) advancing toward IND, and TN-301, a novel small molecule addressing HFpEF, in Phase 1. The company's platform leverages AAV tropism engineering and cardiac-specific promoters, targeting root genetic causes. Recently, Tenaya presented preclinical data supporting TN-401 and announced ongoing enrollment for TN-201. With a market cap around $185M, it represents an early-stage investment opportunity focusing on a high unmet need in cardiovascular genetic diseases.

Upcoming Catalysts (preview)

• Q2 2026TN-201 Phase 1 interim data readout40% success
• Q3 2026TN-401 IND submission and FDA clearance70% success
• Q4 2026TN-301 Phase 1 safety and biomarker data60% success